Retrospective Review
ISSN 2639-9342
Gynecology & Reproductive Health
Comparison of Adjunctive Use of G-CSF Vs Autologous PRP in IVF Patients
with a Refractory Thin Endometrium: A Retrospective Record Review
Mohamed Iqbal Cassim1, Tasneem Mohamed1*, Yusuf Mohamed Dasoo1, Justin Carlse2, Simoné
Budler2, Erwin Rathipal2, Muhammad Ayob2, Jeanne Saron Nissieh Sokoni2, Suhail Dudhia2 and
Mohamed Fayaaz Cassim2
*
1
BioART Fertility Clinic, Johannesburg, South Africa.
2
University of Witwatersrand, Johannesburg, South Africa.
Correspondence:
Dr. Tasneem Mohamed, BioART Fertility Clinic, Johannesburg,
South Africa, 99 Oxford Road, Saxonwold, Johannesburg 2196,
South Africa.
Received: 01 Nov 2022; Accepted: 02 Dec 2022; Published: 07 Dec 2022
Citation: Cassim MI, Mohamed T, Dasoo YM, et al. Comparison of Adjunctive Use of G-CSF Vs Autologous PRP in IVF Patients
with a Refractory Thin Endometrium: A Retrospective Record Review. Gynecol Reprod Health. 2022; 6(6): 1-9.
ABSTRACT
Background: In Vitro Fertilization (IVF) is an important treatment option in the management of couples with infertility. Sadly, however, failure to
achieve a pregnancy through IVF is not uncommon. Amongst the many causes of IVF failure, implantation failure has emerged as one of the more
common and important factors. The refractory thin endometrium as a cause of recurrent IVF failure has been well documented. The use of either
Granulocyte Colony Stimulating Factor (G-CSF) or autologous Platelet Rich Plasma (PRP) has emerged as potential adjunctive treatments that
may mitigate the rate of implantation failure; however, no conclusive evidence exists to favour the use of one over the other.
Objective: To compare the measured change in endometrial thickness and pregnancy rates in patients with Recurrent implantation Failure (RIF)
and/or thin endometrium following the intrauterine administration of either G-CSF or autologous PRP. In addition, to compare the pregnancy rates
in patients with fluid in the endometrial cavity who underwent either therapy.
Design: A retrospective analysis was conducted on patients who underwent endometrial therapy (either G-CSF or PRP) between January and June 2020.
The measured change in endometrial thickness and the clinical pregnancy outcome of the two groups were compared.
Subjects: 36 patients with a mean age of 40.36 years met the inclusion criteria of the study. 20 received autologous intrauterine PRP treatment
and 16 received intrauterine G-CSF treatment. Both groups were well matched for age, pre-intervention endometrial thickness and embryo quality.
Intervention: Administration of G-CSF (One ampoule Neupogen® (filgrastim)) or PRP (1ml) into the uterine cavity transcervical 48 hours prior
to embryo transfer.
Main Outcome Measures: The change in endometrial thickness measured 48 hours prior to embryo transfer and at the time of embryo transfer
(ET) was compared. Positive clinical pregnancy outcome was determined by a positive serum B-HCG test 10 days post insertion. A statistically
significant difference was set at p=0.05.
Results: There was a statistically significant difference in endometrial expansion post intervention in both the G-CSF and PRP groups. However,
the difference between the two groups did not reach statistical significance (p=0.077). Additionally, the collective pregnancy rate of the total
study population was 44.4% (16 of 36), a significant increase over the expected pregnancy rate in the published literature [1,2]. Of the positive
pregnancies, 9 (56.25%) were in the autologous PRP group and 7 (43.75%) in the G-CSF group. This difference was, however, determined not to
be statistically significant (p=0.603).
Conclusion: Both G-CSF and PRP are effective interventions in the management of the thin refractory endometrium. Both result in significant
endometrial expansion and increased pregnancy rates. Despite a marginally higher endometrial response and pregnancy rate in the PRP group,
the differences in these metrics between the two groups were not statistically significant.
Keywords: Granulocyte Colony Stimulating Factor, Platelet Rich Plasma, thin endometrium, implantation failure, adjunctive therapy.
Gynecol Reprod Health, 2022
Volume 6 | Issue 5 | 1 of 9
Attestation statements
The subjects in this trial have not concomitantly been involved in
other randomized trials. Data regarding any of the subjects in the
study has not been previously published unless specified. Data will
be made available to the editors of the journal for review or query
upon request.
Capsule
A retrospective study to compare the adjunctive use of G-CSF vs
autologous PRP in IVF patients with a refractory thin endometrium
and recurrent implantation failure.
Introduction
Endometrial factors implicated in implantation failure include
an elevated or disrupted patient immune response, chronic
endometritis (CE), decreased endometrial gene regulation, and
suboptimal endometrial thickness [3,4]. Endometrial thickness as
a predictor of prognosis in IVF has been controversial. However,
recent meta-analyses have indicated that the thin endometrium
does indeed negatively affect pregnancy outcomes in fresh and
frozen IVF- ET cycles [5,6]. Both pregnancy and live birth rates
decline progressively as endometrial thickness decreases below
8mm [6,7]. Apart from potential implications on pregnancy rates,
a thin endometrium seems to also be associated with other adverse
events, including miscarriages and abnormal placentation [5].
With respect to the thin endometrium, Duraijaj et al., [8] suggests
that this could be due to abnormalities in the decidualization process
because of compromised endometrial stromal cell secretome.
Other etiologies of a thin pre-implantation endometrium include
previous endometrial trauma, decreased endometrial blood flow,
prolonged use of oral contraceptives and the use of estrogen
receptor blockers such as clomiphene citrate [3].
Several treatment modalities have been explored for the thinendometrium related implantation failure. They can be broadly
grouped into three approaches, each exploiting different
mechanisms to increase endometrial thickening and receptivity.
These treatments include hormonal (estrogen, GnRH, HCG),
vascular (sildenafil, aspirin, pentoxifylline, neuromuscular
electrical stimulation) or growth factor therapies (G-CSF,
Autologous PRP) respectively. Patients with cured endometritis
had better IVF outcomes than those with chronic endometritis
[9].
The aim of our study was to compare the efficacy of intrauterine
administration of G-CSF to autologous PRP therapy with regards
to endometrial expansion and/or improved pregnancy outcomes
in women with a thin refractory endometrium. Furthermore, to
investigate the effect of G-CSF and autologous PRP on pregnancy
rates in patients with fluid in the endometrial cavity prior to
embryo transfer.
Materials and Methods
A retrospective analysis was conducted of patients treated by
Gynecol Reprod Health, 2022
IVF at the BioART Fertility Centre in Saxonwold, Johannesburg
between January 2020 and June 2020. All patients who underwent
either G-CSF or PRP endometrial therapy with endometrial
thickness less than 8mm were reviewed. Patients at BioART
are routinely offered these adjuvant therapies for either a thin
endometrium or RIF. In the case of suboptimal endometrial
thickness, patients are routinely supplemented with oral estradiol
up to 8mg and if still an inadequate response is noted, a transdermal
estradiol patch is added (50mg Evorel). In addition, all patients
with suboptimal endometrial thickness are given Sildenafil 25mg
orally starting at least 4 days before anticipated ET. All patients
included in this study had endometrium’s refractory to our routine
first-line therapeutic approach and were thus considered for
intrauterine therapy with either G-CSF or PRP. No consensus has
been reached regarding which intrauterine treatment approach
yielded better results, and thus patients included in the study had
been offered either treatment modality indiscriminately. Informed
consent was obtained in all cases.
A total of 47 patients underwent endometrial therapy with either
G-CSF or autologous PRP during the period of January 2020 to
June 2020. 36 patients met the inclusion criteria with respect to
endometrial thickness and embryo quality. 20 patients received
autologous PRP, and 16 patients received G-CSF.
Endometrial thickness was measured using transvaginal
sonography and was measured at the thickest part of the
endometrium along the longitudinal axis. This was recorded as E1
in the data collection tool. All measurements were done 48 hours
before embryo transfer. Another measurement of the endometrial
thickness was then performed immediately prior to embryo
transfer. This reading was recorded in the data collection tool as
E2, whereafter the difference between E1 and E2 was calculated.
We considered a positive serum B-HCG test at 10 days from the
embryo transfer as a chemical pregnancy and a positive pregnancy
outcome. A negative serum B-HCG test at 10 days from the
embryo transfer was regarded as a negative pregnancy outcome.
Grading and Quality of embryos transferred:
The embryos to be transferred were graded on the day of embryo
transfer (Annexure A).
Day 3 (66-72 hours post-insemination) embryo grading criteria
included number of blastomeres, evenness of the blastomeres
and the degree of fragmentation. Day 5 (114-120 hours postinsemination) embryos were graded according to the size or volume
of the blastocoel cavity, inner cell mass, trophectoderm and Zona
Pellucida thickness. For the purposes of this study embryo quality
was further grouped as either good, intermediate, or poor quality
(Annexure B). At least one good quality embryo was transferred
per participant.
Method of transvaginal G-CSF and autologous PRP
administration:
Both interventions were administered at room temperature to avoid
Volume 6 | Issue 5 | 2 of 9
any adverse effects such as uterine spasm or vaso-vagal responses.
A semi-rigid embryo transfer catheter was used for infusion. The
optimum position for catheter placement was estimated using the
most recent ultrasound findings. We aimed to place the catheter
tip at the mid-cavity level. One ampoule of G-CSF [Neupogen®
(filgrastim) 1 ml], or autologous PRP of the same quantity was
instilled into the uterine cavity, ensuring that the complete volume
of fluid was discharged.
Method of autologous PRP preparation:
8 anticoagulant tubes of peripheral venous blood were collected
per patient. The vials were then immediately balanced and
centrifuged at 3000 revolutions per minute for 5 minutes. From the
three layers, the upper plasma layer of all vials was then removed
until there was at least 0.3ml of buffy coat. The buffy coats and a
little bit of the erythrocyte layer was then placed in a separate tube.
This was then centrifuged for a second time at 3000 revolutions
per minute for a further 5 minutes. The intermediate PRP layer was
then pipetted out and, where required, supplemented with serum to
make up the volume of 1ml.
Figure 1: Histogram of Age Distribution of the study population.
Ethics
Ethical clearance for this study was granted by the University
of Witwatersrand Human Research and Ethics Committee. (No
M191107).
Data Analysis
All patient identifiable data was removed. Data was exported
to Statistica version 14.0.0.15 TIBCO Software Inc. (2020).
Data Science Workbench, version 14 (http://tibco.com) for data
analysis. Categorical variables were described using frequencies and
percentages, whereas continuous variables were described using means
(with Standard deviation). Categorical variables were compared using
Fisher exact test. Continuous variables were compared using student
t-test and Wilcoxon Mann Whitney u- test. A difference was noted to
be statistically significant if the p value was less than 0.05.
Results
Study Population
A total of forty-seven women underwent embryo transfer with
either PRP or G-CSF between the period of 1 January 2020 to 30
June 2020. Thirty-six women met the relevant criteria and were
included in the study. A total of twenty women received PRP and
sixteen received G-CSF as an adjunct therapy.
i) Age:
The ages of the participants ranged from twenty-six to fifty-six. The
mean age was 40.36 (SD +/- 6.77) and the median age was 39.50
(IQR 45.00-37.00) (Figure 1). The PRP group had a mean age of
40.45 (SD +/- 7.26) and median age of 39.00 (IQR 42.75-34.75)
compared with the group treated with G-CSF who had a mean age
of 40.25 (SD +/- 6.33) and median age of 39.00 (IQR 42.75-34.75)
(Figures 2 and 3). The two groups were not significantly different
with respect to their ages (p-value= 0.469).
Gynecol Reprod Health, 2022
Figure 2: Histogram of Age Distribution in PRP group.
ii) Smoking History:
Only one patient had a history of being a smoker and she formed
part of the PRP group. The remainder of the women in the study
were life-long non-smokers. Thus, there was also no significant
difference between the smoking histories of the women that
received PRP and G-CSF respectively (p-value= 0.556).
iii) BMI Classification:
No significant difference in BMI was noted between the two
groups (p-value=0.160).
iv) HIV Status:
A total of seven participants in the study were HIV positive, with the
remaining 29 women being HIV negative. In the PRP group, five of the
twenty were HIV positive (25%), with two in the G-CSF group (12.5%).
Volume 6 | Issue 5 | 3 of 9
Figure 4: Histogram of Number of previous failed IVF cycles in the study
population.
Figure 3: Histogram of Age Distribution in G-CSF group.
The frequency of HIV in the study population and the respective groups
is indicated in Table 1 below. There was no significant difference in
the two groups with respect to HIV status (p-value= 0.307).
HIV
STATUS
Autologous PRP
Freq
Positive 5
Negative 15
Freq
Per
25.00 %
75.00 %
Total Study
Population
G-CSF
2
14
Freq
Per
12.50 %
87.50 %
7
29
Per
19.44 %
80.56 %
Table 1: Freq: Frequency; Per: Percentage.
Fertility History:
i) Number of previous IVF cycles:
As indicated in Figure 4, the participants in the study had a history
of between 0 to 9 previous failed attempts at IVF. The mean
number of previously failed IVF cycles was 2.17 (SD +/- 1.58)
and a median of 2 (IQR 1.25-0.75). The PRP group of women
had a history of 0 to 6 previous failed attempts at IVF (Figure
5) with a mean of 2.1 (SD +/- 1.33) and median 2 (IQR 2.751.75). The G-CSF group had a history of 1 to 9 previous failed
attempts at IVF (Figure 6) with a mean of 2.25 (SD +/- 1.88)
and median of 2 (1.25-0.75). There is no significant difference
between the number of previously failed IVF cycles in the two
groups (p-value= 0.765).
Figure 5: Histogram of Number of previous failed IVF cycles in the PRP
group.
ii) Fluid present in cavity:
Table 2 indicates the frequencies of fluid in the endometrial cavity
in the study population in each of the two groups. Six of the study
participants had fluid in their endometrial cavity prior to the
embryo transfer and of these 4 received G-CSF and 2 received
PRP. There is no significant difference between the G-CSF and
PRP group with regards to the presence of fluid in the endometrial
cavity (p-value= 0.227).
Figure 6: Histogram of Number of previous failed IVF cycles in the
G-CSF group.
Gynecol Reprod Health, 2022
Volume 6 | Issue 5 | 4 of 9
FLUID PRESENT
Autologous PRP
IN ENDOMETRIAL CAVITY
Present
Absent
Total Study
Population
G-CSF
Freq
Per
Freq
Per
Freq
Per
2
18
10.00 %
90.00 %
4
12
25.00 %
75.00 %
6
30
16.67 %
83.33 %
Table 2: Freq: Frequency; Per: Percentage.
Cycle Specific Data:
i) Number of embryos transferred:
Between 1 and 3 embryos were transferred during each transfer
cycle. The mean number of embryos transferred was 2.19 (SD +/0.62) and median of 2 (IQR 3-2) as seen in Figure 7. The PRP
group had a mean of 1.95 (SD +/- 0.61) and a median of 2 (IQR
2-2) embryos transferred (range 1 to 3). The G-CSF group had a
mean of 2.50 (SD +/- 0.52) and median of 2.50 (IQR 3-2) number
of embryos transferred (Range 2 to 3). Figures 8 and 9 indicate the
distribution of the number of embryos transferred in the respective
groups. A statistically significant difference was demonstrated
between the two respective groups with regards to the number of
embryos transferred (p-value= 0.009).
Figure 9: Histogram of Number of embryos transferred in the G- CSF
group.
ii) Type of embryos transferred:
Two of the participants in the G-CSF group had a fresh embryo
transfer. All remaining participants had frozen embryo transfer
using the GnRH protocol. Embryo frequencies are indicated in
table 3 below. No statistically significant difference was noted
between the two groups with regards to the type of embryos
transferred (p-value= 0.078).
iii) Grading of Embryos:
A total number of 77 embryos of varying quality were transferred
during the study. For the purposes of this study, these embryos
were classified as good, intermediate, and poor quality (Appendix
A and Table 3). No statistically significant difference was found
between the quality of embryos that were transferred to each of the
respective intervention groups (p-value= 0.450).
Figure 7: Histogram of Number of embryos transferred in the study
population.
EMBRYO
QUALITY
Good
Intermediate
Poor
Autologous PRP
Freq
28
10
0
Per
73.68 %
26.32 %
0.00 %
G-CSF
Freq
23
15
1
Per
58.97 %
38.46 %
2.56 %
Total Study
Population
Freq
Per
51
64.94 %
25
24.68 %
1
0.00 %
Table 3: Freq: Frequency; Per: Percentage.
Figure 8: Histogram of Number of embryos transferred in the PRP group.
Gynecol Reprod Health, 2022
Change in Endometrial thickness
Participants in the autologous PRP group had an endometrial
thickness ranging from 1.00 mm to 7.60 mm prior to receiving
PRP. The mean endometrial thickness was 6.58 mm (SD +/- 1.56
mm) prior to the intervention. After PRP insertion, the endometrial
thickness ranged from 5.90 mm to 10.70 mm with a mean of 7.98
(SD +/- 1.41 mm). Comparison of the endometrial thickness prior
to PRP and after PRP administration using a paired t-test shows a
mean expansion of 1.41 mm with 95% Confidence Interval (0.871.94) and is statistically significant with p<0.0001 (Figure 10 and
Table 4).
Volume 6 | Issue 5 | 5 of 9
Paired t test
Variable
xnum_e2
xnum_e1
diff
Obs
16
16
16
Mean
Std. Err.
7.5
0.554602
6.55625 0.5815188
0.94375 0.3044077
Std. Dev.
[95% Conf Interval]
2.218408
2.326075
1.217631
6.317894 - 8.682106
5.316772 - 7.795728
0.2949203 - 1.59258
Mean (diff) = mean (xnum_e2 – xnum_e1)
t = 3.1003
Ho: mean (diff) = 0
degrees of freedom = 15
Ha: mean (diff) < 0
Ha: mean (diff) !=0
Ha: mean (diff) > 0
Pr (T < t) = 0.9963
Pr ( |T| > |t| ) = 0.0073
Pr (T > t) = 0.0037
Table 5
Figure 10: Boxplot of Endometrial thickness prior to and after autologous
PRP administration.
Paired t test
Variable
xnum_e1
xnum_e2
diff
Obs
Mean
Std. Err.
Std. Dev.
[95% Conf Interval]
20
20
20
6.575
7.98
-1.405
0.3479924
0.3154445
0.2577713
1.556269
1.410711
1.152788
5.846644 - 7.303356
7.319767 - 8.640233
-1.944522 - 0.8654784
The change in endometrial thickness for the PRP group ranged
from 0.30 mm to 4.90 mm, whereas for the G-CSF group it ranged
from 0.1 mm to 5.0 mm. A Mann Whitney u-test was done to
compare the change in endometrial thickness for the respective
interventions. This indicates that the change in the endometrial
thickness for the PRP group (median: 1.05; Q1:0.63; Q3: 1.83)
is not significantly greater than that of the change in endometrial
thickness for the G-CSF group (median: 0.60; Q1: 0.53; Q3: 1.30)
(U: 104.50; p-value= 0.077). Figure 12 indicates the comparison
of the change in endometrial thickness for the two interventions.
Mean (diff) = mean (xnum_e1 – xnum_e2)
t = -5.4506
Ho: mean (diff) =0
degrees of freedom = 19
Ha: mean (diff) < 0
Ha: mean (diff) !=0
Ha: mean (diff) > 0
Pr (T < t) = 0.0000
Pr ( |T| > |t| ) = 0.0000
Pr (T > t) = 1.0000
Table 4
The G-CSF group had an endometrial thickness ranging from 3.10
mm to 7.80 mm prior to intervention, with a mean endometrial
thickness of 6.56 mm (SD +/- 2.33 mm). After receiving G-CSF, the
endometrial thickness ranged from 5.9 mm to 10.80 mm with a mean
of 7.50 (SD +/- 2.22 mm). Comparison of the endometrial thickness
prior to and post G-CSF insertion using a paired t-test shows a mean
expansion of 0.94mm with 95% Confidence Interval (0.29-1.59). This
is statistically significant with p=0.007 (Figure 11 and Table 5).
Figure 12: Boxplot of change in endometrial thickness in both the PRP
and G-CSF groups.
Pregnancy outcomes:
16 of the 36 women in the study had a positive pregnancy B-HCG
test 10 days post ET. Of these, 9 received PRP and 7 received
G-CSF as shown in Table 6 below. No statistically significant
difference was noted between the two intervention groups (p-value
= 0.604), in terms of pregnancy outcomes.
PREGNANCY
OUTCOME
Figure 11: Boxplot of Endometrial thickness prior to and after G-CSF
administration.
Gynecol Reprod Health, 2022
Positive
Negative
Autologous PRP
Freq
9
11
Per
45.00 %
55.00 %
G-CSF
Freq
7
9
Per
43.75 %
56.25 %
Total Study
Population
Freq
Per
16
44.44 %
20
55.56 %
Table 6: Freq: Frequency; Per: Percentage.
Volume 6 | Issue 5 | 6 of 9
The combined pregnancy rate in the intervention group was
44.44% with 16 out of 36 participants having established a
positive pregnancy test. In the same period as our study, a total of
494 women underwent routine IVF therapy and embryo transfer
without any adjunct therapies. Of these, 194 women had a positive
pregnancy outcome with the overall pregnancy rate of 39.27%.
This comparison is shown in Table 7 below. It is noted that the
difference between the two groups was found not to be statistically
significant (p-value= 0.352), which implies that patients receiving
treatment had a pregnancy rate comparable to those undergoing
routine IVF therapy. Importantly, this indicates that following
therapy, patients with thin endometrium refractory to treatment
achieve a pregnancy rate similar to patients who do not require
such intervention.
Additionally, the pregnancy rate for the intervention group
is substantially higher than that noted in the literature for
patients with similar baseline endometrial thickness without
any intervention. Reference pregnancy rates for frozen embryo
transfers were noted to be 27.4%, 23.7% and 15.0% in patients
with endometrial thickness of 7.0-7.9mm, 6.0-6.9mm and 5.05.9mm respectively [6]. It is important to note that in our study,
no control group was included as it was deemed unsuitable by the
authors to withhold potentially beneficial treatment from patients
with thin endometrium.
PREGNANCY
OUTCOME
Study Population
(G-CSF and PRP)
Freq
Positive
Negative
IVF with no endometrial
therapy
Freq
Per
44.44 %
55.55 %
16
20
Per
39.27 %
60.73 %
194
494
Table 7
Presence of endometrial fluid and pregnancy outcomes in each
of the respective interventions:
2 patients in the PRP group and 4 in the G-CSF group had fluid in
the endometrial cavity 48 hours prior to embryo transfer. A 50%
positive pregnancy rate was observed in both groups; hence no
difference was noted. This is shown in Table 8 below.
In Participants with Fluid in The Endometrial Cavity
PREGNANCY
Autologous PRP
OUTCOME
Freq
Positive
Negative
1
1
G-CSF
Freq
Per
50.00 %
50.00 %
2
2
Per
50.00 %
50.00 %
Table 8
Discussion
The refractory thin preimplantation endometrium and fluid
in the uterine cavity prior to ET remains a challenge for ART
practitioners. Both have been independently associated with failed
IVF-fresh and frozen ET cycles. Several causative factors have
been postulated, including elevated or disrupted immune response,
chronic endometritis, decreased endometrial gene regulation,
abnormalities in the decidualization process, endometrial trauma
Gynecol Reprod Health, 2022
and decreased endometrial blood flow [3]. Many of these factors
are not reversable or curable.
Treatment modalities to date include “Endometrial Scratch”,
fluid extraction, intravaginal or oral Sildenafil, Estrogen
supplementation, electro- acupuncture, and the intrauterine
administration of G-CSF and PRP. It is yet unclear which treatment
options, singularly or in combination, will provide the optimum
outcome.
Granulocyte colony stimulating factor (G-CSF), also known
as colony stimulating factor 3 (CSF-3), is a polypeptide
hematopoietic growth factor and cytokine that regulates the
formation of polymorphonuclear neutrophils [10]. A study
conducted by Fujii et al. [11] has shown that G-CSF may lead
to improved reendothelialization and micro-vessel formation by
elevating serum levels of the angiogenic cytokine Hepatocyte
Growth Factor (HGF). It has also been suggested that G-CSF
affects implantation through a poorly understood mechanism by
acting on decidual macrophages [12]. The efficacy of intrauterine
administration of G-CSF in expanding the thin endometrium in
patients with thin endometrium was noted initially by Barad, et al.
[13] and substantiated by others [14]. To the contrary, the metaanalysis by Li, et al. [15] found that “G-CSF was ineffective in
increasing the endometrial thickness among infertile women
undergoing IVF”, but that the “implantation rate, biochemical
pregnancy rate, and clinical pregnancy rate were significantly
higher”. However, a more recently updated meta- analysis by Xi
et al., showed significant increase in endometrium thickness and
clinical pregnancy rates following intrauterine administration of
G-CSF [1].
Platelet rich plasma (PRP) is plasma derived from whole blood that
has been enriched with platelets. Platelets contain several useful
growth factors such as vascular endothelial growth factor (VEGF),
epidermal growth factor (EGF), platelet derived growth factor
(PDGF), transforming growth factor (TGF) and other cytokines
that stimulate cell proliferation [16]. It has been widely used in
disciplines such as orthopedics and ophthalmology, mainly for
its wound healing properties. A study by Chang, et al. in 2015
[17] showed that 5 women, all with poor endometrial response to
standard IVF therapy, displayed successful endometrial expansion
and pregnancy after the intrauterine administration of autologous
PRP. Although the exact mechanism of action of the PRP has not
yet been described, it has been proposed that the growth factors
play a role in proliferation, apoptosis, inflammation, cell adhesion,
chemotaxis, and immune responses during embryo implantation and
further promotes the formation of decidual blood vessels, placental
angiogenesis, and endometrial proliferation [18]. These properties
potentially explain why women who receive this therapy generally
show a significant improvement in their endometrial thickness and
pregnancy outcomes as was observed in a randomized control trial
by Eftekhar, et al. [2]. In contrast to the conclusions of these studies,
a recent narrative review by Sharara et al. [19] which reviewed
literature focusing on the use of PRP therapy in reproductive
Volume 6 | Issue 5 | 7 of 9
medicine from databases including PubMed, MEDLINE and
CINAHL Plus, found that only a few studies showed an increase
in endometrial thickness, chemical and clinical pregnancy rates.
However, Sharara et al. [19] note that lack of standardization of the
PRP preparation and administration is a limitation and that larger
randomized controlled clinical trials would be needed in future.
In terms of intrauterine therapy, it is unclear whether G-CSF or
PRP is the better option. The cost of G-CSF is notably higher than
that of PRP. Results from our study showed that both G-CSF and PRP
caused significant expansion of the endometrium, but no statistically
significant difference was noted between the two groups.
Our study further noted a significant increase in pregnancy rates in
both treatment groups, surprisingly much higher than that reported
previously in the literature. However, due to the small sample size,
no definitive conclusion can be made in this regard. Concerning
the effect on presence of fluid in the endometrial cavity, 50%
of the study population in either group who had fluid in their
endometrial cavities had a successful pregnancy. However, the
patient numbers were extremely small (4 cases), precluding any
definitive conclusions.
Conclusion
Our study showed that the use of G-CSF and PRP intrauterine
therapy for the refractory endometrium as adjunct to first line
estradiol and Sildenafil use is effective in causing endometrial
expansion. A statistically significant increase in endometrial
thickness was observed in both the G-CSF and PRP groups.
However, when comparing the change in endometrial thickness
with respect to each modality of treatment (PRP vs G-CSF), no
statistically significant difference was noted (p-value= 0.077).
Of the 36 participants, 16 achieved a positive clinical pregnancy
outcome as defined by a positive serum B-HCG test, yielding a
positivity rate of 44.4%. Nine of the 16 participants (56.25%)
received PRP, and seven of the 16 (43.75%) received G-CSF.
The inordinately high pregnancy rate in our intervention
population, when benchmarked against literature expectations for
similarly matched endometrial thickness patients not receiving
any intervention deserves special mention. We believe this to be
because in all the patients, intrauterine intervention was used as
an adjunct to first line estradiol and sildenafil pre-treatment. In
the case of the refractory thin endometrium, PRP appears to be
equivalent to G-CSF in both endometrial expansion as well as
pregnancy rates. It is also more affordable and accessible. Larger
future studies are necessary to validate these findings.
Acknowledgments
We acknowledge the following:
- Dr Admire Chikandiwa for his assistance with statistics and
data analysis.
- University of Witwatersrand Faculty of Health Sciences
Biostatistics Department for assistance with statistics and data
analysis.
Gynecol Reprod Health, 2022
References
1. Xie Y, Zhang T, Tian Z, et al. Efficacy of intrauterine perfusion
of granulocyte colony-stimulating factor (G-CSF) for infertile
women with thin endometrium: A systematic review and
meta-analysis. Am J Reprod Immunol. 2017; 78.
2. Eftekhar M, Neghab N, Naghshineh E, et al. Can autologous
platelet rich plasma expand endometrial thickness and improve
pregnancy rate during frozen-thawed embryo transfer cycle?
A randomized clinical trial. Taiwan J Obstet Gynecol. 2018;
57: 810-813.
3. Bashiri A, Halper KI, Orvieto R. Recurrent Implantation
Failure-update overview on etiology, diagnosis, treatment and
future directions. Reprod Biol Endocrinol. 2018; 16: 121.
4. Wang WJ, Zhang H, Chen ZQ, et al. Endometrial TGF-β,
IL-10, IL-17 and autophagy are dysregulated in women with
recurrent implantation failure with chronic endometritis.
Reprod Biol Endocrinol. 2019; 17: 2.
5. Ranisavljevic N, Raad J, Anahory T, et al. Embryo transfer
strategy and therapeutic options in infertile patients with thin
endometrium: a systematic review. J Assist Reprod Genet.
2019; 36: 2217-2231.
6. Liu KE, Hartman M, Hartman A. Management of thin
endometrium in assisted reproduction: a clinical practice
guideline from the Canadian Fertility and Andrology Society.
Reprod Biomed Online. 2019; 39: 49-62.
7. Liu KE, Hartman M, Hartman A, et al. The impact of a thin
endometrial lining on fresh and frozen-thaw IVF outcomes: an
analysis of over 40000 embryo transfers. Hum Reprod. 2018;
33: 1883-1888.
8. Peter Durairaj RR, Aberkane A, Polanski L, et al. Deregulation
of the endometrial stromal cell secretome precedes embryo
implantation failure. Mol Hum Reprod. 2017; 23: 478-487.
9. Vitagliano A, Saccardi C, Noventa M, et al. Effects of chronic
endometritis therapy on in vitro fertilization outcome in
women with repeated implantation failure: a systematic review
and meta-analysis. Fertil Steril. 2018; 110: 103-112.e1.
10. Demetri GD, Griffin JD. Granulocyte colony-stimulating
factor and its receptor. Blood. 1991; 78: 2791-2808.
11. Fujii K, Ishimaru F, Kozuka T, et al. Elevation of serum
hepatocyte growth factor during granulocyte colonystimulating factor-induced peripheral blood stem cell
mobilization. Br J Haematol. 2004; 124: 190-194.
12. Barash A, Dekel N, Fieldust S, et al. Local injury to the
endometrium doubles the incidence of successful pregnancies
in patients undergoing in vitro fertilization. Fertil Steril. 2003;
79: 1317-1322.
13. Barad DH, Yu Y, Kushnir VA, et al. A randomized clinical trial
of endometrial perfusion with granulocyte colony-stimulating
factor in in vitro fertilization cycles: impact on endometrial
thickness and clinical pregnancy rates. Fertil Steril. 2014; 101:
710-715.
Volume 6 | Issue 5 | 8 of 9
14. Mohamed T, Adam Y, Cassim MI. An evaluation of the use
of G-CSF as an adjunct to IVF in women who have previously
failed attempts at pregnancy with IVF. IJWHR. 2017; 7: 269275.
15. Li J, Mo S, Chen Y. The effect of G-CSF on infertile women
undergoing IVF treatment: A meta-analysis. Syst Biol Reprod
Med. 2017; 63: 239-247.
16. Zadehmodarres S, Salehpour S, Saharkhiz N, et al. Treatment
of thin endometrium with autologous platelet-rich plasma: a
pilot study. JBRA Assist Reprod. 2017; 21: 54-56.
17. Chang Y, Li J, Li X, et al. Platelet-rich plasma administration
has benefit for infertile women with thin endometrium in
frozen blastocyst-stage embryos transfer program. Fertility
and Sterility. 2017; 108: p.e77.
18. Farimani M, Poorolajal J, Rabiee S, et al. Successful pregnancy
and live birth after intrauterine administration of autologous
platelet-rich plasma in a woman with recurrent implantation
failure: A case report. Int J Reprod Biomed. 2017; 15: 803806.
19. Sharara FI, Lelea LL, Rahman S, et al. A narrative review of
platelet-rich plasma (PRP) in reproductive medicine. J Assist
Reprod Genet. 2021; 38: 1003-1012.
© 2022 Cassim MI, et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
Gynecol Reprod Health, 2022
Volume 6 | Issue 5 | 9 of 9